Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.

B. Riley Securities Maintains Buy on SRAX, Lowers Price Target to $4.5

B. Riley Securities analyst Mike Crawford maintains SRAX (NASDAQ:SRAX) with a Buy and lowers the price target from $7.5 to $4.5.

byBenzinga Newsdesk

January 13, 2023

1 minute read

B. Riley Securities analyst Mike Crawford maintains SRAX (NASDAQ:SRAX) with a Buy and lowers the price target from $7.5 to $4.5.

Wells Fargo Maintains Overweight on Ares Management, Raises Price Target to $92

By Benzinga Newsdesk

Today, 5:57 AM

Wells Fargo analyst Timothy O'Shea maintains Ares Management (NYSE:ARES) with a Overweight and raises the price target from $81 to $92.

ARES

News
Tech

Facebook Targets Apple’s 30% Commission With Latest Move

By Anusuya Lahiri

Today, 5:57 AM

Facebook Inc, rebranded as Meta Platforms Inc (NASDAQ:FB), announced its plans to sneak around Apple Inc’s (NASDAQ:AAPL) infamous platform fees in an ongoing war…

AAPL

FDA
News

FDA Says More Data Needed To Be Certain Pfizer Vaccine Is Safe For Young Children

By Benzinga Newsdesk

Today, 5:57 AM

-Reuters

BNTX

Here’s How Much $100 Invested In CVS Health 20 Years Ago Would Be Worth Today

By Benzinga Insights

Today, 5:57 AM

CVS Health (NYSE:CVS) has outperformed the market over the past 90 days by 9.58%, generating a 13.55% return for its investors over the time period. Now, given this information, it may seem like price appreciation alone is the best way to have made money on this stock, that's not actually the case.

CVS

B. Riley Securities Maintains Buy on SRAX, Lowers Price Target to $4.5

Related Posts

Wells Fargo Maintains Overweight on Ares Management, Raises Price Target to $92

Facebook Targets Apple’s 30% Commission With Latest Move

FDA Says More Data Needed To Be Certain Pfizer Vaccine Is Safe For Young Children

Here’s How Much $100 Invested In CVS Health 20 Years Ago Would Be Worth Today